Topic

Articles

Operational and patient burden considerations for self-collection of blood specimens in clinical trials

Self-collection of Blood Specimens in Clinical Trials

A look forward to 2021 for the clinical trials industry.

2021 Promises for Clinical Trials

EVP and General Manager of Hū, April Lewis, discusses why the industry has seen a decline in trial participation and what Hū is doing to combat it.

Industry Forced to Rethink Patient Participation in Trials

Regulatory concerns remain despite industry's quick adaptation of decentralized trials.

Decentralized Trials, Pros and Cons

The industry wide shift to decentralized clinical trials includes considerations for sponsors and CROs such as global availability, global technology, and data integration. 

Harness Technology to Scale Global Hybrid Decentralized Studies

Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.

Employing the Power of Bayesian Methods to Expedite Learning

Both quality personnel and the FDA have predicted some of the issues with pandemic operations, but much is still unknown on the impact these rapidly implemented pandemic processes.

Clinical Trial Quality Concerns Arise Amidst COVID

Randomized controlled trials establish strict inclusion and exclusion criteria in an effort to optimize the cohort of trial participants.

Real-World Evidence Studies can Enhance Diversity and Equity in Clinical Research

Findings from a Tufts study examining the effects of COVID-19 on clinical trials.

COVID-19 and Its Impact on the Future of Clinical Trial Execution

Tips for reducing site queries and improving workflows.

Trial Design